A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Ductal Adenocarcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. No evidence of disease progression or recurrence at any time prior to the first study treatment.
    2. Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy (if applicable) to Grade 1 or less (except alopecia

You may not be eligible for this study if the following are true:

    1. History of other malignancy =3 years from initiation of study treatment except for: A. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of any site, which were treated with local resection only 


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.